Background: The aim of this review is to bring pancreatic transplantation out of the specialist realm, informing practitioners about this important procedure, so that they feel better equipped to refer suitable patients for transplantation and manage, counsel and support when encountering them within their own speciality.
Introduction
Diabetes is the pandemic disease of the modern era, since 1996, the number of people diagnosed with diabetes in the UK has risen from 1.4 million to an estimated UK prevalence of over 5 million suffers by 2025. Ten percent of these patients have type 1 diabetes mellitus (T1DM), of which 29 000 are children. 1 The UK has the world's fifth highest rate of type 1 diabetes in children, according to an international league table compiled by Diabetes UK. 24.5 per 100 000 children aged 0-14 in the UK are diagnosed with the condition every year. Of all the countries with data, only Finland, Sweden, Saudi Arabia and Norway have higher rates. The rate in the UK is over double that in France (12. 2) and Italy (12.1).
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Acute diabetic complications include diabetic ketoacidosis and non-ketotic hyperosmotic coma for type 1 and type 2 diabetes, respectively. Serious chronic complications for both include micro and macrovascular diseases such as heart disease, strokes, renal failure, blindness and limb amputation. The standard treatment for many diabetics includes therapeutic interventions to lower blood sugar levels with either oral or injected medication to aim to limit these complications. Injectable exogenous insulin has been available for patients with diabetes since 1922, and the majority of patients remain well controlled on this basis. However, a proportion of patients go on to develop life-threatening complications of diabetes failing to respond to the most careful insulin regimes. These patients, in whom there is a failure of effective medical therapy, can be classed as: progression of diabetes, complications of renal failure and instability of glycemic control presenting as hypoglycaemic unawareness. 3 Pancreas transplantation remains the best opportunity to maintain normoglycaemia with full insulin independence. In excess of 40 000 pancreas transplants have been recorded worldwide curing T1DM. The procedure has shown to reduce and in some cases reverse diabetic complications. Prolonging and improving the quality and duration of patient's lives makes pancreas transplantation an excellent NHS funded treatment for a small but severely disadvantaged proportion of patients who have the most severe complications of diabetes. Type 1 diabetes complications usually include kidney failure (for which a kidney transplant is also performed) or intractable problems with sugar control (for which the pancreas is transplanted alone). 4 Currently there are four types of pancreatic transplant:
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History of pancreas transplantation
In 1893, an attempt was made to graft three pieces of sheep pancreas into the subcutaneous tissue of a diabetic child. Despite initial success, the patient died after 3 days because of severe ketoacidosis. The first successful human pancreas transplant was performed in December 12, 1966 at the University of Minnesota by the team of Doctors Kelly, Lillehei, Merkel, Idezuki and Goetz. A pancreas along with kidney and donor duodenum was transplanted into a 28-year-old woman who became insulin independent, but died a short time later due to pulmonary embolism. 5, 6 Outcomes improved with time and significantly when simultaneously performing a pancreas with kidney transplant as the kidney graft functioned as a sentinel for rejection. In PTA without a kidney, results were significantly inferior as rejection was often missed. Exocrine pancreas drainage was managed using duodenocystostomy so that urinary amylase could be measured as a way of monitoring the pancreas graft in patients. However, the loss of sodium bicarbonate passing out with urine created severe metabolic acidosis, and in extreme cases, extracellular volume depletion required hospitalization. Frequent documented complications include chemical cystitis, urethritis, bladder leak, reflux pancreatitis, recurrent infections, bladder cancer, bladder stones, urethral strictures, urethral irritation, epididymitis, prostatitis and prostatic abscess.
As immunosuppression regimes improved, these complications since have been avoided through a switch to enteric drainage where the head of the pancreas is joined to the small intestine using a duodenal conduit, which was introduced in late 1990s. 7 
Immunosuppression
Immunosuppressive therapy initially began with non-depleting antibodies but has since been replaced with antibody induction therapy as an optimum method of suppressing lymphocytes. From 1980 to 2000, patients received triple immunosuppression with cyclosporine, azathioprine and prednisone. But following 2000, immunosuppression was intensified by induction therapy for both pancreas and kidney transplants with the use of anti T cell induction using polyclonal antithymocyte antiglobulin (ATG) or monoclonal anti-CD-25-directed therapy in the form of basiliximab or daclizumab antagonizing interleukin 2-receptors, and the T cell depleting antibody alemtuzumab known as Campath, Genzyme. 8 T cell depletion during induction reduces the number and severity of biopsy proven rejection episodes but does not have effect on survival rates. Over time Azathioprine has been replaced by Mycophenolate Mofetil (MMF) and Cyclosporine by Tacrolimus, which are the two most common medications transplant patients take to maintain their life lifelong immunosuppression, both showing improved outcomes compared to their predicesors. 8, 9 Both Cyclosporine and Tacrolimus are classed as calcineurin inhibitors, which overtime cause cytotoxicity. Calcineurin inhibitors suppress the immune system by preventing interleukin-2 (IL-2) production in T cells. Both molecules inhibit the phosphatase action of calcineurin, which is required for the movement of nuclear factors in activated T cells to the chromosomes where subsequent cytokine synthesis occurs. Decreased secretion of IL-2 prevents proliferation of the inflammatory response via B cells and T cells. The attenuated inflammatory response greatly reduces the overall function of the immune system. Belatacept is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T-cell co-stimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. 9 What do I need to know about donation?
The majority of pancreas grafts are retrieved from heart-beating brain dead donors (DBD), with an increase in number seen from non-heart-beating donors after circulatory death (DCD). Overall, solid organs offered for pancreas transplantation remain underused due to the strict acceptance criteria of transplant units. The acceptance criteria include Body Mass Index (BMI), age of donor, alcohol and lifestyle factors. Donor obesity remains a common reason for refusal, as donors with BMI greater than 35 kg/m 2 are more likely to have fatty infiltration of the pancreas, which is a risk factor for posttransplant complications.
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Practitioners can help, by promoting organ donation, encouraging a healthy lifestyle, and preventing donor obesity in order to ensure donated organs is usable. Fatty infiltration of the pancreas is thought to affect the organ in two ways. Firstly lipid droplets can contribute to microvasculature occlusion and graft thrombosis, and also promote inflammation during ischaemic reperfusion leading to allograft pancreatitis.
Other criteria for donation include: hyperglycaemia related to cerebral injury of the donor. This at time of organ retrieval is common and not an absolute contraindication for pancreas organ use, but is a minor risk factor for long-term graft loss, so different units have varying policies on what levels they will accept. High amylase levels can occur for a number of reasons and again, not an absolute contraindication for organ use unless there is proven pancreatitis or damage due to trauma. Extreme age is also a contraindication to donation; and although there is variation between units, donors over 60 are unlikely to be used for transplant, as are donors with BMIs over 30 kg/m 2 .
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How is it technically performed?
The traditional retrieval procedure involves removal of the pancreas en-bloc with the donor duodenum and spleen. The pancreas is then separated from the spleen prior to implantation. During this preparation for implantation, the pancreas has its two supply arteries (superior mesenteric artery and splenic artery) joined to create a single arterial inflow. This is done with the aid of a 'Y' or 'trouser' graft commonly utilizing the donor common iliac artery and its bifurcation. The portal vein, which provides venous drainage, is inspected to ensure adequate length and absence of damage. All small branches and lymphatics are also tied off to ensure haemostasis at reperfusion. A short duodenal conduit for exocrine drainage is also prepared carefully to prevent leaks (see Figs 1 and 2 ). The implantation operation involves a midline laparotomy to gain access to the peritoneal cavity, the small bowel and right colon are mobilized to expose the abdominal aorta, IVC and iliac vessels which are carefully dissected out.
The next stage of the surgery involves connecting the blood vessels of the donor pancreas to the recipient vasculature. The donor Portal Vein is commonly anastomosed to the recipient's right Common Iliac Vein or Inferior Vena Cava. The donor artery is usually anastomosed to the recipients' right common iliac artery. The final part of the operation involves making a connection between the donor duodenal conduit and the recipients small bowel to drain the digestive juices that the pancreas produces. Usually a twolayer hand sewn side to side enteric anastomosis is performed. Alternatively, the duodenal conduit can be anastomosed to the recipients' bladder if bladder drainage is desired (see Fig. 3 ).
Transplanting a pancreas alone takes~3-4 h. A simultaneous pancreas and kidney transplant takes 4-6 h. In an SPK transplant procedure, the pancreas is placed on the right side of the abdomen and the kidney on the left. The native pancreas and kidney remain in place.
Contraindications to surgery?
Absolute contraindications to surgery include significant cardiovascular disease with severe or noncorrectable coronary artery disease, cardiac ejection fraction of less than 50%, recent myocardial infarction, non-curable malignancy-excluding localized skin cancer, active sepsis, active peptic ulcer disease, severe psychiatric conditions leading to noncompliance, inability to survive surgery or immunosuppression due to other significant comorbidity.
Relative contraindications include cerebrovascular event with long-standing impairment; human immunodeficiency virus; hepatitis B and C viruses; a body mass index more than 30; extensive vascular, aortic and renal artery disease (making surgery high risk); excessive need for insulin greater than 1.5 U/kg/d; and continuous use of alcohol, smoking, and other drugs. Age is also a consideration, with the median age of recipients being roughly 40 years old, while patients above 60 are less likely to be considered for transplantation. 11, 12 What are the benefits?
Transplantation restores glucagon secretion, returns hepatic glucose production to normal, improves lipid profiles and insulin mediated protein kinetics. Clinical improvements have been observed in diabetic nephropathy, neuropathy, gastroparesis, retinopathy (microvascular and macrovascular disease), cardiac function and sexual function. There is also some evidence for patients with diabetic nephropathy, showing reversal of glomerular and cortical lesions due to diabetic nephropathy. One study showed almost complete normalization of glomerular structure 10 years post-transplant. 12 The diabetes control and complication trial showed pancreas transplantation lowers HbA 1c to within normal limits even after 10 years, with mean HbA 1c at 6 years being 6% compared to 7% of those being treated by intensified insulin regimes. Thus restoring glycaemic control and improving glucose counter regulation. Several studies have also reported improvement of lipid metabolism. 13 Quality of Life & Survival is also hugely improved. SPK transplantation has been shown in several studies to increase observed versus expected lifespan, when compared to kidney transplant alone, however other studies have had conflicting results. SPK recipients had the highest longevity, 23.4 years compared with 20.9 years for live kidney transplant and 12.8 years for deceased donor kidney transplant. 14 Evidence shows PAK recipients have improved patient and kidney graft survival as a result of pancreas transplantation, with significantly higher GFRs seen in PAK patients compared with kidney transplant alone, suggesting the optimization of glycaemic control is beneficial. 15 Common consensus suggests Pancreas transplantation remains an improved quality of life operation, however the reduced long-term mortality seen compared to mortality rates on the waiting list, does extend life in some patients. Evidence suggests that there are significant improvements in quality of life, a greater satisfaction with life, health, social and sex life, having more feelings of control and independence and better perceptions of social and mental health following pancreas transplantation. 16 
What are the risks?
As with all operations there is a risk of bleeding, with a significant bleed requiring a return to theatre occurring in~5% of patients. The most common cause of non-immunogenic graft failure is graft thrombosis with a reported incidence ranging from 5% to 25%. Increased use of anticoagulants in the early post-op period aims to reduce the rate of thrombosis. 17 Other risks include enteric anastomotic leak, graft pancreatitis and intra-abdominal sepsis. Allograft pancreatitis is common, affecting 40% of patients. Severe graft pancreatitis and can lead to life-threatening respiratory compromise as well as graft dysfunction, and is associated with a significantly increased length of hospital stay. The high morbidity associated with pancreas transplantation is one of the factors leading to its long-term stagnation as a therapy, especially in private healthcare models where additional interventions as a result of complications impact on the cost effectiveness. Careful observation, regular imaging, use of antimicrobial agents and optimal donor organ selection all help minimize complications through prophylaxis and early detection.
Various modern antibody induction therapies and complex immunosuppression regimes are used to prevent rejection. Donor specific antibodies (DSA) can be made against the graft at any time despite immunosuppression and cause rejection and potential loss of the graft so monitoring of antibodies through blood tests is essential. 18 Immunosuppressants also reduce the ability to fight infection. Extreme vigilance is therefore necessary to detect and treat the early signs of infection to prevent the development sepsis. Patients are often spared steroids where possible and commonly discharged on Tacrolimus and Mycophenolate Mofetil to maintain immunosuppression. The common side effects of the immunosuppressant drugs include tremors, increased blood pressure, hair loss, mood changes and neutropenia. 19 What is the long-term outlook?
The International Pancreas Transplant Registry (IPTR) reports the 5-year survival rate following pancreas transplantation is 87% after SPK, 83% after PAK and 89% after PTA. At 15 years survival falls to 56% for SPK patients (36% with a functioning graft), 42% for PTA patients (18% with a functioning graft) and 59% for PAK patients (16% with a functioning graft). IPTR data analyses have consistently used insulin independence as the definitive criterion for graft survival. The estimated transplant graft half-life (graft surviving with 50% function) has also improved, with an average half-life of 14 years after SPK, and 7 years for both PTA and PAK. The longest documented pancreas graft survival offering insulin independence was 26 years after SPK, 24 years after PAK, and 23 years after PTA. 20 In the UK, the 2016 NHSBT annual report shows that graft survival is 87% at 1 year, 75% at 5 years, and 65% at 10 years. One of the reasons for the significant decline in graft survival is the absence of validated biomarkers to predict rejection or graft failure in pancreas transplantation. As such, by the time that abnormal endocrine or exocrine function is detected, the damage is often irreversible with patients rapidly returning to insulin therapy. 21 More than 90% of pancreas-rejection episodes are thought to be reversible if detected in the absence of hyperglycaemia. These episodes can be identified using transplanted kidneys as surrogate markers if they are from the same donor, or direct biopsy of the pancreas in response to changes in biochemical markers or clinical presentation. Recent evidence suggests the discordance rates of rejection between kidney and pancreas are more frequent, promoting the need to biopsy the pancreas in order to confirm pancreatic rejection. Reported rejection rates are 5-25% depending on what immunosuppressive regime is used. Acute rejection is an important risk factor for long-term graft loss as a result of chronic rejection and the formation of DSAs. Hyperglycaemia is associated with a low probability of reversing the rejection episode. 23, 24 In March 2016, there were 227 patients on the UK active pancreas and islet transplant list, which represents a 6% decrease in number of patients a year earlier. The number of patients on the active pancreas list decreased by 8% to 199 in 2016 while the active islet transplant list decreased by 22% to 28 patients in the same time period. There were 2219 pancreas transplants performed in the UK in the 10-year period and 183 islet transplants performed in the 8 years since islet transplantation was first commissioned in the UK. The number of transplants from donations after brain death has decreased slightly in the last year to 161. However, the number of transplants from donations after circulatory death has decreased by 17% in the last year to 52.
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This falling rate is mirrored across the globe; the reasons for which are complex, but thought to be due to fewer candidates during this time have been added to the pancreas waiting list, and the increasing prevalence of type II diabetes as well as the change in habitus of donors. With improved glycaemic control using continuous insulin pumps the stagnation in the advances of this procedure since its start in 1966 are now being seen. Short waiting lists and a significant postoperative complication burden, typically in excess of 50%, makes a clear argument to for using optimal organs rather than marginal. However, this commits pancreas transplantation to a niche role, confined to highly selected patients and donor organs, effectively ignoring the potential benefits of this therapeutic modality in a wider cohort of patients with advanced diabetes. Consequently, the rate of discarded organs resulting from having such specific donor criteria is high; in excess of 40% in most countries that perform pancreas transplantation. As well as limiting the number of patients who could benefit from pancreas transplantation, this has clear financial implications in the cost of organ procurement. 25 
Future direction
As technology advances, new devices to improve blood glucose monitoring and insulin therapy are being developed to reduce the risk of hypoglycaemia. Continuous glucose monitoring (CGM) devices through real time monitoring both invasively using implanted needles or non-invasive methods such as microwave assessment allow insulin pumps to continually secrete insulin through a closed loop system. Current limitations with delivery, absorption and dosing still exist, but are continual evolving. 26, 27 Advances over the last decade show generating functional beta cells from stem cells is achievable and have the benefit of not only transplanting beta cells but also Somatostatin, alpha and ghrelin cells all through to have a role in insulin homoeostasis. Better understanding beta-cell development including, the signalling pathways that instruct endocrine progenitor cells to differentiate into mature and functional beta cells is critical as well as finding solutions to make these cells viable once transplanted. Other issues include large-scale generation of transplantation quality beta cells using cost effective models, as volume of cells seems to be an important feature, with exponential losses seen during ischaemia reperfusion. The risk of neoplasia using progenitor cells is always a concern and with current therapies remaining experimental there is much safety data yet to be collected. 28 One of the key questions, which remain unanswered, is which is better: Whole pancreas transplantation or islet transplant? With islets only making up 1-2% of the pancreas and the morbidity associated with the procedure, it seems a poignant question. Currently there is no trial comparing the outcomes of these two therapies and so creates an opportunity for future research.
Gene therapy is also being explored as a potential cure for diabetes, with evidence supporting differentiated cells, such as other types of pancreas cells and liver cells, which can be stimulated to secrete insulin, from their own proinsulin genes. This if successful may eliminate the need for pancreas transplant all together. 29 Another idea, is the first scientific report demonstrating perfusion decellularization technology in vital organs was demonstrated by Ott et al. Using recent approaches to develop synthetic scaffolds and decellularized tissue have achieved a more complex level of tissue organization in organs, with some success in clinical trials. 30 Spider silk has also been used to create a scaffold with initial animal trials looking encouraging. The concept of decellularization technology has also been applied to produce whole organderived scaffolds by removing cellular content while retaining the extracellular matrix and necessary vascular and structural cues of the native organ, in hope to rebuild the whole organ. In the context of pancreas transplantation, this is still a experimental concept but may promote a change in the future direction of travel.
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Conclusion
Since the first pancreas transplant in 1966, pancreas transplantation has evolved from an experimental procedure to the gold standard of care for patients with type 1 diabetes and uraemia. Currently, it remains the most effective method of establishing and maintaining euglycaemia over the longer term, halting and potentially reversing many of the secondary complications associated with diabetes. It has extended its reach being used in some T2DM patients showing significant improvements to quality of life and better life expectancy.
However, little evolution and a change in the donor habitus combined with high morbidity rates have resulted in it pancreas transplantation being an endangered procedure with real fear of extinction. Curing diabetes is one of the greatest challenges our society has to face, and the burden of this disease is huge. Pancreas transplantation definitely has a place within this arena but is well overdue a change bringing it truly into the 21 st century as a viable and effective option for the many rather than select few.
